Prices delayed by at least 15 minutes | Print


ICU Medical (ICUI)

Common Shares
Sell: $107.02|Buy: $107.36|Change: 0.72 (0.68%)

Open 

$106.19


Previous close 

$106.38


Trade high 

$108.94


Volume 

291,915


Year high 

$208.48


Year low 

$78.28


Dividend yield 

-


Market capitalisation 

$2.61 bn


P/E ratio 

333.33


ISIN 

US44930G1076


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 10/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
ICU Medical+ 0.68
More...

Company profile

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems(28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.